Insider · CIK 0001657720

Deschatelets Pascal

Reports to the SEC for 1 company · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001657720

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-05-14	APLSApellis Pharmaceuticals, Inc.U Disposition from Tender	Chief Scientific Officer	UDisposition from Tender	−1.18M sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.A Award	Chief Scientific Officer	AAward	+41.3K sh	—	—	41,250
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−41.3K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.A Award	Chief Scientific Officer	AAward	+10K sh	—	—	10,030
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−10K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.A Award	Chief Scientific Officer	AAward	+12.9K sh	—	—	12,920
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−12.9K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.A Award	Chief Scientific Officer	AAward	+25.8K sh	—	—	25,840
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−25.8K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−4,909 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−3,372 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−11.3K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−25.8K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−109K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−82.5K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−110K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−95K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−51K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−56.3K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−45K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−30.8K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−9,805 sh	—	—	0
2026-01-28	APLSApellis Pharmaceuticals, Inc.A Award	Chief Scientific Officer	AAward	+25.8K sh	—	—	1,177,222
2026-01-22	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−5,928 sh	$21.77	−$129K	1,151,382
2026-01-20	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−909 sh	$19.79	−$18K	1,157,310
2026-01-13	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−2,277 sh	$22.19	−$50.5K	1,158,219
2025-06-09	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Scientific Officer	AAward	+82.5K sh	$19.39	+$1.6M	82,500
2025-05-21	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+12.8K sh	$3.76	+$48.1K	1,160,496
2025-05-21	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−12.8K sh	—	—	0
2025-01-29	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−826 sh	$29.52	−$24.4K	1,147,716
2025-01-22	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−3,948 sh	$30.43	−$120K	1,148,542
2025-01-21	APLSApellis Pharmaceuticals, Inc.A Award	Chief Scientific Officer	AAward	+15K sh	—	—	1,152,490
2025-01-17	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−750 sh	$29.96	−$22.5K	1,137,445
2025-01-13	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−2,288 sh	$28.70	−$65.7K	1,138,195
2024-05-20	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+24.5K sh	$3.76	+$92.1K	1,140,483
2024-05-20	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−24.5K sh	—	—	12,780
2024-05-08	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+78.9K sh	$4.31	+$340K	1,194,890
2024-05-08	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−56.3K sh	$42.15	−$2.37M	1,138,555
2024-05-08	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−22.5K sh	$42.85	−$963K	1,116,083
2024-05-08	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−100 sh	$44.02	−$4,402.5	1,115,983
2024-05-08	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−78.9K sh	—	—	108,622
2024-04-08	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+69.1K sh	$3.76	+$260K	1,185,090
2024-04-08	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−64.4K sh	$54.12	−$3.48M	1,120,711
2024-04-08	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−4,728 sh	$54.92	−$260K	1,115,983
2024-04-08	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−69.1K sh	—	—	37,280
2024-03-08	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+69.1K sh	$3.67	+$254K	1,185,090
2024-03-08	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−42.8K sh	$61.88	−$2.65M	1,142,340
2024-03-08	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−26.3K sh	$62.69	−$1.65M	1,116,083
2024-03-08	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−100 sh	$63.35	−$6,335	1,115,983
2024-03-08	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−69.1K sh	—	—	106,387

Recent filings

Accepted (ET)
May 144
Deschatelets Pascal0001193125-26-224609
SEC(opens sec.gov)

Companies

Apellis Pharmaceuticals, Inc.Chief Scientific OfficerAPLS

Address

C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR

WALTHAM, MA, 02451